Announcement PDF ASX Announcement Dapsone 5%, Gel Licensing partnership in Saudi Arabia Melbourne, Australia; 31 July 2025; Acrux Limited (ASX: ACR) Acrux has executed a Sales, Marketing, Distribution and License Agreement with Servacure Trading W.L.L. (‘Servacure’) for Dapsone 5%, Gel for Saudi Arabia. Dapsone 5%, Gel was developed by Acrux and was successfully launched through a licensee in the United States in April 2024. It is approved by the Food and Drug Administration (‘FDA’) to be marketed in both a 60 gram and the recently launched 90 gram pack size and is indicated for the treatment of acne vulgaris. The contract term with Servacure is for 10 years with options for renewal at the end of this term. Servacure will assume responsibility for obtaining regulatory approval as well as coordinating manufacturing for the Territory and will pay Acrux a fixed fee per unit for the aggregate unit volume of all product shipped to customers during a calendar month. Acrux CEO and Managing Director, John Warmbrunn said: “I have many years of experience in the dynamic pharmaceutical market the Kingdom of Saudi Arabia so I am pleased to be partnering our first product with Servacure. They have a demonstrated track record of commercialising their products in the Saudi marketplace and we look forward to a long-term relationship with them across the range of products in our portfolio. This type of geographic expansion leverages our US FDA approvals to penetrate other countries and generate increased return from existing investments. It is a good example of Acrux’s potential for licensing US FDA approved products around the globe.” Authorised by the Board of Directors. For more information, please contact John Warmbrunn Acrux Limited CEO & Managing Director P: + 61 3 8379 0100 E: john.warmbrunn@acrux.com.au About Acrux Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit www.acrux.com.au About Servacure Servacure is a private limited company established 2014, offering brands of high quality which add great value to customers. Servacure’s vision is to be an international company specialising in marketing and promoting pharmaceuticals and medical devices of high quality through business partnerships with international companies leveraging their experience, professionality and know-how, to expand business activities throughout the Middle East and North America region. For more information: https://www.servacure.com/